Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease

Polycystic liver disease is the most common extra-renal manifestation of autosomal dominant polycystic kidney disease (ADPKD). There is need for robust long-term evidence for the volume-reducing effect of somatostatin analogues. We made use of data from an open-label, randomized trial to determine the effects of lanreotide on height-adjusted liver volume (hTLV) and combined height-adjusted liver and kidney volume (hTLKV) in patients with ADPKD.

Source: Gastroenterology - April 21, 2019 Category: Gastroenterology Authors: Rene M.M. van Aerts, Wietske Kievit, Hedwig M.A. D'Agnolo, Charles J. Blijdorp, Niek F. Casteleijn, Shosha E.I. Dekker, Johan W. de Fijter, Maatje van Gastel, Tom J. Gevers, Liyanne F.M. van de Laarschot, Marten A. Lantinga, Monique Losekoot, Esther Meije Source Type: research